regorafenib造句

• Regorafenib shows anti-VEGFR2-TIE2 tyrosine kinase inhibition.
• After a manufacturer's appeal Regorafenib was restored to the list.
• Several other molecules followed up, such as Vemurafenib, Regorafenib, Dabrafenib, etc.
• Regorafenib is a compound developed by Bayer.
• Another phase III trial is comparing cobimetinib with atezolizumab and regorafenib for treament of advanced colorectal cancer.
• However, three medications have been identified for clinical benefit in GIST : imatinib, sunitinib, and regorafenib.
• After a manufacturer's appeal Regorafenib was restored to the list of treatments funded by the English Cancer Drugs Fund.
• Regorafenib ( marketed under the trade name Stivarga ), is currently being studied as a potential treatment option in multiple tumor types.
• In 2011, Bayer entered into an agreement with Onyx under which Onyx will receive a 20 percent royalty on any future global net sales of regorafenib in oncology.
• Regorafenib ( Stivarga ) was FDA approved in 2013 for advanced GISTs that cannot be surgically removed and that no longer respond to imatinib ( Gleevec ) and sunitinib ( Sutent ).
• On February 25, 2013, the FDA approved regorafenib in a second indication to treat patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor ( GIST ) who have been previously treated with imatinib mesylate and sunitinib malate.
• On 27 September 2012, the FDA approved regorafenib for the treatment of patients with metastatic colorectal cancer ( CRC ) who have been previously treated with fluoropyrimidine-, oxaliplatin, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild-type, an anti-EGFR therapy.